 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
For more information about this course contact: Martha Tobin Local: Toll Free: Email: |
 |
The Cleveland Clinic Center for Continuing Education acknowledges educational grants for partial support of this activity from: Platinum ANS - A St. Jude Medical Company Gold Medtronic Silver Boston Scientific Bronze Intelect Medical |
US Department of Health and Human Services Office on Disability
in partnership with the Cleveland Clinic presents
Brain Pacemakers:
A Promising Approach and a New Era of Hope
for Neurological Disorders
May 6, 2008
Health and Human Services Hubert H. Humphrey Building
Washington, D.C.
Thank you for your interest in the "Brain Pacemakers: A New Era of Hope for Neurological and Psychiatric Disorders" symposium taking place on Tuesday, May 6, 2008.
Online registration for this program is now closed. Please call Monet Smith at 216-444-9380 or 800-223-2273, ext 49380, for information about registering onsite if space is still available.
 |
|||
 |
For the complete brochure click here (2 MB) |
 |
|
|
|||
OVERVIEW
Deep brain stimulation (DBS) or brain pacemaker technology is an area of rapid growth in medicine with enormous potential for treating various chronic and disabling neurological disorders.
There have been over 40,000 DBS implants worldwide. Currently, the FDA approves DBS in the US for the treatment of movement disorders such as Parkinson disease, essential tremor, and dystonia. In the past decade, the scientific literature has demonstrated the long-term safety and benefit of DBS in the treatment of patients with movement disorders.
In addition, the use of DBS for treating other neurological and neuropsychiatric disorders is currently being explored through various investigational clinical trials. Promising data are emerging regarding the benefit of DBS in the treatment of patients with obsessive compulsive disorder, depression, epilepsy, and traumatic brain injury.
The positive impact of DBS in Americans with neurological disorders and disability cannot be understated. For many patients, DBS therapy is life altering and various studies clearly indicate profound improvements in quality of life for patients who have exhausted most, if not all, other treatment options. This innovative approach also brings forth ethical challenges that need to be considered. In this symposium, we will review the current indications for DBS and its multifaceted impact on patient’s lives, and will explore emerging applications for clinical practice and the future direction of the field.
The program will include prominent guests and leading faculty representing clinicians, neuroscientists, patients, patient advocacy groups, and representatives from various government agencies.
We are honored to have as distinguished speakers:
- Andrew C. von Eschenbach, MD, Commissioner of the Food and Drug Administration
- Rear Admiral Steven K. Galson, MD, MPH, Health and Human Services Acting Surgeon General.
- The Honorable Bill Pascrell, Jr., New Jersey 8th Congressional District, Co-Chair, Congressional Brain Injury Task Force
- Michael Kinsley, Journalist
Lectures and discussion will focus on the impact of this technology on patients’ quality of life, level of functioning, and return to work. Emphasis will also be placed on access to care, medical innovation, healthcare economics and ethics. The format will consist of didactic lectures and video presentations followed by panel discussions and audience questions and answers.
After completing participation in this activity, the participant will be able to:
- Describe the basic rationale and components of Deep brain stimulation.
- Review the current FDA approved clinical indications for DBS.
- Discuss the emerging applications and preliminary findings for deep brain stimulation for those with disabling neurological and psychiatric disorders.
- Examine the ethical considerations associated with brain pacemaker technology.
- Discuss research and future applications.
- Describe neurological and psychiatric disorders and their associated impairment, disability, suffering and compromise to quality of life.
- Discuss the impact of the disease on patients, families and the cost to society.
- Biomedical Engineers
- Centers for Disease Control
- Centers for Medicare and Medicaid Services
- Department of Defense
- Department of Health & Human Services
- Food and Drug Administration
- Health Care Practitioners
- Indian Health Services
- Medical Device Industry
- National Institutes of Health
- Patient Advisory Groups on Parkinson Disease, Essential Tremor, Dystonia, Psychiatric Disorders and Traumatic Brain Injury
- Patients and Families
- Physicians
- Scientists
- Substance Abuse and Mental Health Services Administration
- Veterans Administration
| Margaret Giannini, MD, FAAP | Office on Disability US Department of Health and Human Services Washington, DC |
| Ali R. Rezai, MD | Cleveland Clinic Center for Neurological Restoration Cleveland, OH |
| Kristen Bowsher (invited) |
FDA, Division of Restorative Devices
Rockville, MD |
| David Charles, MD | Vanderbilt University Nashville, TN |
| John Corrigan, PhD | Ohio State University Columbus, OH |
| Ann Costello (invited) |
FDA, Division of Restorative Devices Rockville, MD |
| Joseph Fins, MD | Weill Cornell Medical Center New York, NY |
| Joseph Giacino, PhD | JFK Johnson Rehabilitation Institute Edison, NJ |
| Wayne Goodman, MD | National Institutes of Mental Health Rockville, MD |
| Steven Grant | National Institute on Drug Abuse Bethesda, MD |
| Ben Greenberg, MD | Brown University Providence, RI |
| Michael Kinsley | Seattle, WA |
| Col. Robert Labutta, MD | Army Office of the Surgeon General Falls Church, VA |
| Fred Lenz, MD | Johns Hopkins University Baltimore, MD |
| Peter LeWitt, MD | Wayne State University/Clinical Neuroscience Center Southfield, MI |
| Col. Geoffrey Ling, MD, PhD | DARPA/DSO Arlington, VA |
| Donald Malone, MD | Cleveland Clinic Cleveland, OH |
| Helen Mayberg, MD | Emory University Atlanta, GA |
| James McNulty | National Alliance for the Mentally Ill |
| Maria Mouratidis, PsyD | National Naval Medical Center Bethesda, MD |
| Joseph Pancrazio | NINDS/NIH Neuroscience Center 2205 Rockville, MD |
| Steve Phurrough, MD, MPA |
Centers for Medicare and Medicaid Services Baltimore, MD |
| Nicholas Schiff, MD | Weill Medical College of Cornell University New York, NY |
| Ashwini Sharan, MD | Thomas Jefferson university Philadelphia, PA |
| Andrew C. von Eschenbach, MD | US Food & Drug Administration Rockville, MD |
|
|
| TUESDAY, May 6 |
|
|
|
| 8:15 am | Welcome Margaret Giannini, MD Director, Office on Disability and Program Co-Chair |
| 8:25 am | Opening Remarks Distinguished Guest |
| 8:35 am | KEYNOTE ADDRESS Medical Device Innovation: Improving the Healthcare and Quality of Life for Americans Andrew C. von Eschenbach, MD Commissioner, US Food & Drug Administration |
|
|
DBS: Progress and Promise |
|
|
|
| 8:55 am | Deep Brain Stimulation: A Scientific Primer Fred Lenz, MD Johns Hopkins University |
| 9:05 am | Current State of DBS Ali R. Rezai, MD Cleveland Clinic and Program Co-Chair |
| 9:25 am | DBS: Ethical Considerations Joseph J. Fins, MD Weill Cornell Medical College |
| 9:45 am | Break |
|
|
Movement Disorders |
|
|
|
| 10:00 am | A Conversation with Michael Kinsley |
| 10:15 am | DBS for Parkinson’s Disease: Outcomes and Quality of Life Changes David Charles, MD Vanderbilt University |
| 10:30 am | DBS for Essential Tremor and Dystonia: Outcomes and Quality of Life Changes Peter LeWitt, MD Wayne State University |
| 10:45 am | Panel Discussion |
| Moderator: Joseph Pancrazio, PhD, NINDS/NIH Panelists: • DBS Patient • David Charles, MD, Vanderbilt University • Peter LeWitt, MD, Wayne State University • Steve Phurrough, MD, MPA, Director, Coverage and Analysis Group, Centers for Medicare and Medicaid |
|
|
|
Epilepsy |
|
|
|
| 11:15 am | Epilepsy and Impact on Disability Martha Morrell MD Stanford University |
| 11:25 am | DBS for Epilepsy Ashwini Sharan, MD Thomas Jefferson University |
| 11:35 am | Discussion - DBS Patient |
| 11:45 am | Lunch Break |
| 12:45 pm | SPECIAL PRESENTATION Rear Admiral Steven K. Galson, MD, MPH Acting US Surgeon General |
|
|
Psychiatric Disorders |
|
|
|
| 1:00 pm | Emerging Neuroscience of Psychiatric Disorders Wayne Goodman, MD NIMH |
| 1:15 pm | DBS for Obsessive Compulsive Disorder and Depression Benjamin Greenberg, MD Brown University |
| 1:30 pm | DBS: Targeting Depression Helen Mayberg, MD Emory University |
| 1:45 pm | DBS for Psychiatric Disorders: Outcomes And Quality of Life Donald Malone, MD Cleveland Clinic |
| 1:55 pm | Panel Discussion |
| Moderator: Benjamin Greenberg MD, Brown University Panelists: • OCD DBS Patient • Depression DBS Patient • Steven Grant, PhD, NIDA • Ann Costello, FDA, Division of Restorative Devices • James Mc Nulty, National Alliance for the Mentally Ill |
|
| 2:30 pm | Break |
|
|
Traumatic Brain Injury (TBI) |
|
|
|
| 2:50 pm | TBI and Long Term Disability – The TBI Model Systems of Care John Corrigan, PhD Ohio State University |
| 3:00 pm | TBI & PTSD in the Military • Col. Robert Labutta, MD Office of the Surgeon General • Maria Mouratidis, PsyD National Naval Medical Center |
| 3:20 pm | DBS for TBI: Restoring Functional Capacity • Nicholas Schiff, MD Weill Cornell Medical College • Joseph Giacino, PhD JFK Johnson Rehabilitation Institute |
|
|
Future Directions: From Research to Therapy |
|
|
|
| 3:40 pm | Future Directions Ali R. Rezai, MD, Cleveland Clinic |
| Moderator: Joseph J. Fins, MD, Weill Cornell Medical College Panelists: • Kristin Bowsher, FDA, Division of Restorative Devices • Wayne Goodman, MD, NIH/NIMH • Benjamin Greenbery, MD, Brown University • Joseph Pancrazio, PhD, NIH/NINDS • Michael Kinsley, Journalist • Ali Rezai, MD, Cleveland Clinic • Steve Phurrough, MD, MPA, Centers for Medicare and Medicaid |
|
| 4:20 pm | Closing Comments Margaret Giannini, MD and Ali R. Rezai, MD |
|
|
FACULTY DISCLOSURE
The Cleveland Clinic Foundation Center for Continuing Education has implemented a policy to comply with the current Accreditation Council for Continuing Medical Education Standards for Commercial Support requiring resolution of all faculty conflicts of interest. Faculty declaring a relevant commercial interest will be identified in the activity syllabus.
LOCATION
Health and Human Services Hubert H. Humphrey Building
200 Independence Avenue S.W.
Washington, D.C., 20201
PARKING
There are several public parking lots in the area with varying rates as well as metered parking up to 2 hours.
Locations of parking lots/garages open to the public:
• 3rd & E Streets SW
• 4th & C Streets SW
• 6th & C Streets SW
ACCREDITATION
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This activity may be submitted for American Osteopathic Association Continuing Medical Education credit in Category 2.
ADDITIONAL INFORMATION
For further information, please contact:
Martha Tobin
Telephone: 216-445-3449 or 800-223-2273 ext 53449
E-mail: tobinm@ccf.org
ONLINE REGISTRATION
This course uses our online registration system which instantly approves credit card transactions and issues you a receipt immediately.
Instructions for first time users:
- Login initially by selecting a registration category (Physician, Nurses, etc) from the drop down menu.
- Provide your personal information (name, address, telephone, and a 4 digit number password of your choice). The password is required and will serve as your login identification for all future registrations.
- Select course options and enter your information in the next screen.
For questions about registering online, call 216-448-0777.
| Category | Fee |
| All Registrants | complimentary |